HUGE vs. BIVI, FLGC, KALA, VINC, RNXT, LUMO, YMTX, ONTX, GLTO, and SYBX
Should you be buying FSD Pharma stock or one of its competitors? The main competitors of FSD Pharma include BioVie (BIVI), Flora Growth (FLGC), KALA BIO (KALA), Vincerx Pharma (VINC), RenovoRx (RNXT), Lumos Pharma (LUMO), Yumanity Therapeutics (YMTX), Onconova Therapeutics (ONTX), Galecto (GLTO), and Synlogic (SYBX). These companies are all part of the "pharmaceutical preparations" industry.
FSD Pharma (NASDAQ:HUGE) and BioVie (NASDAQ:BIVI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, community ranking, media sentiment, profitability, valuation and dividends.
In the previous week, FSD Pharma had 1 more articles in the media than BioVie. MarketBeat recorded 5 mentions for FSD Pharma and 4 mentions for BioVie. BioVie's average media sentiment score of 0.34 beat FSD Pharma's score of 0.21 indicating that BioVie is being referred to more favorably in the news media.
BioVie has a consensus target price of $8.00, indicating a potential upside of 1,555.63%. Given BioVie's higher possible upside, analysts plainly believe BioVie is more favorable than FSD Pharma.
FSD Pharma has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500. Comparatively, BioVie has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500.
1.2% of FSD Pharma shares are held by institutional investors. Comparatively, 4.6% of BioVie shares are held by institutional investors. 8.5% of FSD Pharma shares are held by company insiders. Comparatively, 4.8% of BioVie shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
BioVie received 16 more outperform votes than FSD Pharma when rated by MarketBeat users.
FSD Pharma is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks.
FSD Pharma's return on equity of -112.38% beat BioVie's return on equity.
Summary
BioVie beats FSD Pharma on 7 of the 13 factors compared between the two stocks.
Get FSD Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for HUGE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HUGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
FSD Pharma Competitors List
Related Companies and Tools
